STUELPNAGEL JOHN R 4
4 · 10x Genomics, Inc. · Filed Nov 3, 2021
Insider Transaction Report
Form 4
STUELPNAGEL JOHN R
Director
Transactions
- Sale
Class A Common Stock
2021-11-01$163.89/sh−2,906$476,264→ 356,916 total - Sale
Class A Common Stock
2021-11-01$160.33/sh−100$16,033→ 361,516 total - Sale
Class A Common Stock
2021-11-01$160.75/sh−100$16,075→ 361,416 total - Sale
Class A Common Stock
2021-11-01$161.52/sh−100$16,152→ 361,316 total - Sale
Class A Common Stock
2021-11-01$163.10/sh−1,494$243,669→ 359,822 total - Sale
Class A Common Stock
2021-11-01$164.58/sh−300$49,374→ 356,616 total
Footnotes (4)
- [F1]The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $162.50 to $163.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]This transaction was executed in multiple trades at prices ranging from $163.50 to $164.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F4]This transaction was executed in multiple trades at prices ranging from $164.55 to $164.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.